These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16175313)

  • 1. Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery.
    Lagneau F; Marty J; Beyne P; Tod M
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):1-32. PubMed ID: 16175313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery.
    Lanckohr C; Horn D; Voeller S; Hempel G; Fobker M; Welp H; Koeck R; Ellger B
    J Thorac Cardiovasc Surg; 2016 Aug; 152(2):603-10. PubMed ID: 27209020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women.
    Swank ML; Wing DA; Nicolau DP; McNulty JA
    Am J Obstet Gynecol; 2015 Sep; 213(3):415.e1-8. PubMed ID: 26003059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section?
    Kram JJF; Greer DM; Cabrera O; Burlage R; Forgie MM; Siddiqui DS
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():334-341. PubMed ID: 28122314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery.
    Young OM; Shaik IH; Twedt R; Binstock A; Althouse AD; Venkataramanan R; Simhan HN; Wiesenfeld HC; Caritis SN
    Am J Obstet Gynecol; 2015 Oct; 213(4):541.e1-7. PubMed ID: 26103528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass.
    Ingrande J; Gutierrez K; Lemmens HJ; Verma A; Nicolau DP; Sutherland CA; Ramamoorthy C
    Anesth Analg; 2019 May; 128(5):935-943. PubMed ID: 30995208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue pharmacokinetics of cefazolin in patients with lower limb infections.
    Bhalodi AA; Housman ST; Shepard A; Nugent J; Nicolau DP
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5679-83. PubMed ID: 24041887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates.
    De Cock RF; Smits A; Allegaert K; de Hoon J; Saegeman V; Danhof M; Knibbe CA
    J Antimicrob Chemother; 2014 May; 69(5):1330-8. PubMed ID: 24492261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of Pharmacokinetic Basis of Weight-Based Dosing and Intra-Operative Re-Dosing with Cefazolin Surgical Prophylaxis in Obese Patients: Implications for Antibiotic Stewardship.
    Blum S; Cunha CB; Cunha BA
    Surg Infect (Larchmt); 2019 Sep; 20(6):439-443. PubMed ID: 31112072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.
    Brill MJ; Houwink AP; Schmidt S; Van Dongen EP; Hazebroek EJ; van Ramshorst B; Deneer VH; Mouton JW; Knibbe CA
    J Antimicrob Chemother; 2014 Mar; 69(3):715-23. PubMed ID: 24214905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.
    Roberts JA; Udy AA; Jarrett P; Wallis SC; Hope WW; Sharma R; Kirkpatrick CM; Kruger PS; Roberts MS; Lipman J
    J Antimicrob Chemother; 2015 May; 70(5):1495-502. PubMed ID: 25608584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renal function on the pharmacokinetics and pharmacodynamics of prophylactic cefazolin in cardiothoracic surgery.
    Kosaka T; Hosokawa K; Shime N; Taniguchi F; Kokufu T; Hashimoto S; Fujiwara H; Yaku H; Sugioka N; Okada K; Fujita N
    Eur J Clin Microbiol Infect Dis; 2012 Feb; 31(2):193-9. PubMed ID: 21598071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Cefazolin Prophylactic Dosing for Bariatric Surgery: No Need for Higher Doses or Intraoperative Redosing.
    Chen X; Brathwaite CE; Barkan A; Hall K; Chu G; Cherasard P; Wang S; Nicolau DP; Islam S; Cunha BA
    Obes Surg; 2017 Mar; 27(3):626-629. PubMed ID: 27520693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery.
    Grupper M; Kuti JL; Swank ML; Maggio L; Hughes BL; Nicolau DP
    J Clin Pharmacol; 2017 Jun; 57(6):712-719. PubMed ID: 27925657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery.
    De Cock PA; Mulla H; Desmet S; De Somer F; McWhinney BC; Ungerer JP; Moerman A; Commeyne S; Vande Walle J; Francois K; Van Hasselt JG; De Paepe P
    J Antimicrob Chemother; 2017 Mar; 72(3):791-800. PubMed ID: 27999040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting.
    Andreas M; Zeitlinger M; Wisser W; Jaeger W; Maier-Salamon A; Thalhammer F; Kocher A; Hiesmayr JM; Laufer G; Hutschala D
    Eur J Cardiothorac Surg; 2015 Nov; 48(5):758-64. PubMed ID: 25527166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo microdialysis to measure antibiotic penetration into soft tissue during cardiac surgery.
    Hutschala D; Skhirtladze K; Kinstner C; Mayer-Helm B; Müller M; Wolner E; Tschernko EM
    Ann Thorac Surg; 2007 Nov; 84(5):1605-10. PubMed ID: 17954069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial.
    Naik BI; Roger C; Ikeda K; Todorovic MS; Wallis SC; Lipman J; Roberts JA
    Br J Anaesth; 2017 Jun; 118(6):876-882. PubMed ID: 28505360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 years.
    Schmitz ML; Blumer JL; Cetnarowski W; Rubino CM
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4173-80. PubMed ID: 25941220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery.
    Nahata MC; Durrell DE; Ginn-Pease ME; King DR
    Eur J Drug Metab Pharmacokinet; 1991; 16(1):49-52. PubMed ID: 1936061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.